Crinetics Pharmaceuticals, Inc. (CRNX)

84.84 -0.01% (-0.01)

Over 5Y: +282.9%

2026-08-28
25 50 75
2021 2022 2023 2024 2025 2026

Financials Quarterly

Q3 '21 — Revenue: 0 Q3 '21 — Operating Cash Flow: -25.7M Q3 '21 — Free Cash Flow: -25.8M Q3 '21 — Net Income: -27.9M Q4 '21 — Revenue: 0 Q4 '21 — Operating Cash Flow: -22.9M Q4 '21 — Free Cash Flow: -22.9M Q4 '21 — Net Income: -30.8M Q1 '22 — Revenue: 3.1M Q1 '22 — Operating Cash Flow: -13.5M Q1 '22 — Free Cash Flow: -13.6M Q1 '22 — Net Income: -34.6M Q2 '22 — Revenue: 439K Q2 '22 — Operating Cash Flow: -28M Q2 '22 — Free Cash Flow: -28.6M Q2 '22 — Net Income: -42.4M Q3 '22 — Revenue: 458K Q3 '22 — Operating Cash Flow: -38.5M Q3 '22 — Free Cash Flow: -39.2M Q3 '22 — Net Income: -41.9M Q4 '22 — Operating Cash Flow: -35.2M Q4 '22 — Free Cash Flow: -35.5M Q4 '22 — Net Income: -45M Q1 '23 — Revenue: 2.7M Q1 '23 — Operating Cash Flow: -40.7M Q1 '23 — Free Cash Flow: -40.7M Q1 '23 — Net Income: -46M Q2 '23 — Revenue: 988K Q2 '23 — Operating Cash Flow: -45.7M Q2 '23 — Free Cash Flow: -46M Q2 '23 — Net Income: -51M Q3 '23 — Revenue: 346K Q3 '23 — Operating Cash Flow: -41.3M Q3 '23 — Free Cash Flow: -44.8M Q3 '23 — Net Income: -57.5M Q4 '23 — Revenue: 0 Q4 '23 — Operating Cash Flow: -40.8M Q4 '23 — Free Cash Flow: -41.7M Q4 '23 — Net Income: -60.1M Q1 '24 — Revenue: 640K Q1 '24 — Operating Cash Flow: -52.9M Q1 '24 — Free Cash Flow: -54.2M Q1 '24 — Net Income: -66.9M Q2 '24 — Revenue: 399K Q2 '24 — Operating Cash Flow: -47.6M Q2 '24 — Free Cash Flow: -48.6M Q2 '24 — Net Income: -74.1M Q3 '24 — Revenue: 0 Q3 '24 — Operating Cash Flow: -62.8M Q3 '24 — Free Cash Flow: -63.4M Q3 '24 — Net Income: -76.8M Q4 '24 — Revenue: 0 Q4 '24 — Operating Cash Flow: -66.9M Q4 '24 — Free Cash Flow: -67.9M Q4 '24 — Net Income: -80.6M Q1 '25 — Revenue: 361K Q1 '25 — Operating Cash Flow: -88.5M Q1 '25 — Free Cash Flow: -89.7M Q1 '25 — Net Income: -96.8M Q2 '25 — Revenue: 1M Q2 '25 — Operating Cash Flow: -85.9M Q2 '25 — Free Cash Flow: -89.1M Q2 '25 — Net Income: -115.6M Q3 '25 — Revenue: 143K Q3 '25 — Operating Cash Flow: -110.7M Q3 '25 — Free Cash Flow: -111.6M Q3 '25 — Net Income: -130.1M Q4 '25 — Revenue: 6.2M Q4 '25 — Operating Cash Flow: -92.9M Q4 '25 — Free Cash Flow: -93.4M Q4 '25 — Net Income: -122.8M Q1 '26 — Revenue: 10.7M Q1 '26 — Operating Cash Flow: -124.7M Q1 '26 — Free Cash Flow: -125.5M Q1 '26 — Net Income: -127.8M Q2 '26 — Revenue: 25.1M Q2 '26 — Operating Cash Flow: -94.2M Q2 '26 — Free Cash Flow: -94.7M Q2 '26 — Net Income: -120.9M -105M -70M -35M 0 35M
Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.6
SBC / sales 234.8%
OE margin -1243.4%
Oper. margin -1302.5%
Accruals -6.0%
Asset turnover 0.032×
EBITDA margin -1292.5%
FCF margin -1008.6%
OCF margin -1002.3%
Profit margin -1189.9%
ROA -37.9%
ROCE -44.2%
ROE -42.1%
Gross margin —
OCF / EBIT —
ROIC —

4 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.3
RPO / sales 0.04×
RPO growth —
Segment HHI —

4 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

7.5
Current ratio 15.9×
ND/EBITDA —
Cash runway 2.8 yr
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 15.5×
F-score 2.2 pts
Cash / Debt —
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

6.6
Sales/sh Y/Y +2500.8%
Sales Q/Q +2336.3%
Shares change +16.4%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales CAGR 4Y —

2 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.